COMMUNIQUÉS West-GlobeNewswire

Communiqué : Point sur l'obtention des autorisations des autorités de la concurrence dans le cadre du projet de rapprochement entre Essilor et Luxottica
24/07/2017
Point sur l'obtention des autorisations des autorités de la concurrence dans le cadre du projet de rapprochement entre Essilor et Luxottica Version PDF du communiqué Charenton-le-Pont, France et Milan, Italie (le 24 [...]
News Release: Antitrust process update for the proposed combination between Essilor and Luxottica
24/07/2017
Antitrust process update for the proposed combination between Essilor and Luxottica PDF Version of the news release Charenton-le-Pont, France and Milan, Italy (July 24, 2017) - The proposed combination between Essilor ( [...]
Ossur Hf : Transactions in relation to share buyback program
24/07/2017
Announcement from Össur hf. No. 51/2017 Reykjavík, 24 July 2017 On 1 December 2016, Össur hf. initiated a new share buy-back program, see Company announcement no. 96/2016. The purpose of the share buyback program is to [...]
Oriola Corporation - Repurchase of own shares on 24 July 2017
24/07/2017
ORIOLA CORPORATION STOCK EXCHANGE RELEASE 24 JULY 2017 AT 18:45 EEST In the Nasdaq Helsinki Date 24 July 2017 Exchange transaction Buy Share trading code OKDBV Amount, shares 16.657 Average price/share, EUR 3,5601 Total [...]
Innocoll and Gurnet Point Announcement relating to the Scheme becoming Effective
24/07/2017
NOT FOR RELEAS E, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF THAT JURISDICTION FOR IMMEDIATE [...]
Corning and Gerresheimer Collaborate to Deliver New Corning Valor(TM) Glass to the Pharmaceutical Packaging Market
24/07/2017
Remarkable glass innovation enables enhanced quality parenteral packaging CORNING, N.Y. and DUSSELDORF, GERMANY; JULY 24, 2017 - Corning Incorporated (NYSE: GLW) and Gerresheimer AG announce that they are accelerating [...]
Minerva Neurosciences Announces Departure of Directors
24/07/2017
WALTHAM, Mass., July 24, 2017 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ:NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system disorders, [...]
Novo Nordisk A/S - Share repurchase programme
24/07/2017
Bagsværd, Denmark, 24 July 2017 - On 2 February 2017, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No. 596/2014 of the European Parliament and Council of 16 April 2014 ( [...]
LIDDS: Clarification regarding signed research agreement
24/07/2017
With reference to press release LIDDS signs research agreement with major European pharma company, published 21 July 2017 at 10:00 CET, we hereby announce that the agreement party is Ferring Pharmaceuticals. Contact [...]
DEINOVE renforce la fonction de Business Développement avec l'arrivée de Sébastien Enault
24/07/2017
Sébastien Enault apporte à la Société une expérience confirmée dans la mise en place de collaborations dans le domaine pharmaceutique et notamment dans celui des anti-infectieux. Montpellier, le 24 juillet 2017 (8h30 [...]
DEINOVE strengthens its Business Development activity with the arrival of Sébastien Enault
24/07/2017
Sébastien Enault brings to the Company a proven track record in the development of collaborations in the pharmaceutical field and, in particular, in the anti-infective field. Montpellier, 24 July 2017 (8:30am CEST) - [...]
Xbrane Biopharma AB: Spherotide granted Market Authorization in Iran
24/07/2017
Press release 2017-07-24 Xbranes partner Pooyesh Darou has been granted Market Authorization for sales and marketing of Spherotide 1 month formulation in Iran under the local brand name Microrelin®. "This is a major [...]
ABLYNX ANNOUNCES WARRANT EXERCISE
24/07/2017
REGULATED INFORMATION GHENT, Belgium, 24 July 2017 - Ablynx [Euronext Brussels: ABLX; OTC: ABYLY] today announced, in conformity with Title II of the Law of 2 May 2007 and the Royal Decree of 14 February 2008, that an [...]
VALNEVA reçoit le statut de "Fast Track" de la FDA pour son candidat vaccin contre la maladie de Lyme VLA15
24/07/2017
Valneva reçoit le statut de "Fast Track" de la FDA pour son candidat vaccin contre la maladie de Lyme VLA15 Lyme est la maladie infectieuse transmise par vecteur qui se développe le plus rapidement aux Etats-Unis, selon [...]
VALNEVA Receives FDA Fast Track Designation for its Lyme Disease Vaccine Candidate VLA15
24/07/2017
Valneva Receives FDA Fast Track Designation for its Lyme Disease Vaccine Candidate VLA15 Lyme disease is the fastest growing vector-borne infectious disease in the United States, according to the CDC; Currently, there [...]
Innocoll Announcement Relating to the Outcome of the Court Sanction Hearing
21/07/2017
NOT FOR RELEAS E, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF THAT JURISDICTION FOR IMMEDIATE [...]
Sanofi and Regeneron Receive Positive CHMP Opinion for Dupixent® (dupilumab) to Treat Adult Patients with Moderate-to-Severe Atopic Dermatitis
21/07/2017
Sanofi and Regeneron Receive Positive CHMP Opinion for Dupixent ® (dupilumab) to Treat Adult Patients with Moderate-to-Severe Atopic Dermatitis - First investigational targeted biologic in the European Union to receive [...]
Sanofi et Regeneron obtiennent un avis favorable du CHMP pour Dupixent® (dupilumab) dans le traitement de la dermatite atopique modérée à sévère de l'adulte
21/07/2017
Sanofi et Regeneron obtiennent un avis favorable du CHMP pour Dupixent ® (dupilumab) dans le traitement de la dermatite atopique modérée à sévère de l'adulte - Premier traitement biologique expérimental ciblé à obtenir [...]
Novartis receives positive CHMP opinion for Rydapt® (midostaurin) for newly diagnosed FLT3-mutated acute myeloid leukemia (AML) and three types of advanced systemic mastocytosis (SM)
21/07/2017
Recommendation based on largest trial in FLT3-mutated AML to date, showing 23% reduction in the risk of death with Rydapt treatment regimen[1] If approved, Rydapt would represent the first targeted treatment for newly [...]

Pages